Yusuke Haba

Dr. Yusuke Haba


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2022 in Breast Cancer
Verified
Journal Article
Closed access
PDF file
Masakuni NoguchiMasakuni Noguchi
Masakuni Noguchi
MIMasafumi Inokuchi
Masafumi Inokuchi
MYMiki Yokoi-Noguchi
Miki Yokoi-Noguchi
EMEmi Morioka
Emi Morioka
YHYusuke Haba
Yusuke Haba

9 November 2023 in Cancers
Verified
Journal Article
Open access
PDF file
Masakuni NoguchiMasakuni Noguchi
Masakuni Noguchi
MIMasafumi Inokuchi
Masafumi Inokuchi
MYMiki Yokoi-Noguchi
Miki Yokoi-Noguchi
EMEmi Morioka
Emi Morioka
YHYusuke Haba
Yusuke Haba
Axillary lymph node dissection (ALND) has been associated with postoperative morbidities, including arm lymphedema, shoulder dysfunction, and paresthesia. Sentinel lymph node (SLN) biopsy emerged as a method to assess axillary nodal status and possibly obviate the need for ALND in patients with clinically node-negative (cN0) breast cancer. The majority of breast cancer patients are eligible for SLN biopsy only, so ALND can be avoided. However, there are subsets of patients in whom ALND cannot be eliminated. ALND is still needed in patients with three or more positive SLNs or those with gross extranodal or matted nodal disease. Moreover, ALND has conventionally been performed to establish local control in clinically node-positive (cN+) patients with a heavy axillary tumor burden. The sole method to avoid ALND is through neoadjuvant chemotherapy (NAC). Recently, various forms of conservative axillary surgery have been developed in order to minimize arm lymphedema without increasing axillary recurrence. In the era of effective multimodality therapy, conventional ALND may not be necessary in either cN0 or cN+ patients. Further studies with a longer follow-up period are needed to determine the safety of conservative axillary surgery.

8 May 2023 in Surgery Today
Verified
Journal Article
Closed access
PDF file
Masakuni NoguchiMasakuni Noguchi
Masakuni Noguchi
EMEmi Morioka
Emi Morioka
MYMiki Yokoi-Noguchi
Miki Yokoi-Noguchi
YHYusuke Haba
Yusuke Haba
MIMasafumi Inokuchi
Masafumi Inokuchi
MHMachiko Hisano
Machiko Hisano

6 November 2023 in Cancers
Verified
Journal Article
Open access
PDF file
Masakuni NoguchiMasakuni Noguchi
Masakuni Noguchi
MIMasafumi Inokuchi
Masafumi Inokuchi
MYMiki Yokoi-Noguchi
Miki Yokoi-Noguchi
EMEmi Morioka
Emi Morioka
YHYusuke Haba
Yusuke Haba
SYSohsuke Yamada
Sohsuke Yamada
Background: Axillary reverse mapping (ARM) nodes are involved in a significant proportion of clinically node-positive (cN+) breast cancer patients. However, neoadjuvant chemotherapy (NAC) is effective at decreasing the incidence of nodal metastases in cN+ patients. Patients and methods: One hundred forty-five cN+ patients with confirmed nodal involvement on ultrasound-guided fine needle aspiration cytology were enrolled in this study: one group underwent axillary lymph node dissection (ALND) without NAC (upfront surgery group), and the other group underwent ALND following NAC (NAC group). The patients underwent 18F-FDG-positron emission tomography/computed tomography (18F-FDG-PET/CT) before surgery, as well as an ARM procedure during ALND. Results: the rates of involvement of ARM nodes in the NAC group were significantly lower than those of the upfront surgery group (36.6% vs. 62.2%, p < 0.01). Notably, involvement was significantly decreased after NAC in non-luminal-type tumors as compared to the luminal-type (18.4% vs. 48.5%: p < 0.01). Moreover, there was a significant difference in ARM node involvement after NAC between patients with or without axillary uptake of 18F-FDG (61.5% vs. 32.5%: p < 0.01). Conclusions: NAC significantly decreased the risk of ARM node metastases in cN+ patients, but 18F-FDG-PET/CT was not suitable to detect residual metastatic disease of the axilla after NAC.

19 May 2026 in Diseases
Verified
Journal Article
Open access
PDF file
CMChikara Mashiba
Chikara Mashiba
ASAkihiro Shioya
Akihiro Shioya
Takanobu TakataTakanobu Takata
Takanobu Takata
MKMotona Kumagai
Motona Kumagai
MSMiyako Shimasaki
Miyako Shimasaki
SYSohsuke Yamada
Sohsuke Yamada
Background/Objectives: Conventional assessments of lymphatic invasion in the primary tumor may fail to identify lymph node metastasis (LNM) in breast cancer. We evaluated periarterial or perivenous invasion (periA/V), using Elastica–van Gieson (EVG)-stained sections, as a histological marker associated with LNM in invasive breast carcinoma of no special type (IBC-NST), focusing on the impact of invasive tumor size. Methods: We retrospectively analyzed 213 IBC-NST cases. PeriA/V was defined as tumor nests in direct contact with perivascular elastic fibers on EVG-stained sections. Diagnostic performance was compared with that of conventional LI markers (hematoxylin and eosin and D2-40), with stratified analyses by pathological T category (pT1 vs. pT2–4) and pT1 subcategories (pT1a, pT1b, and pT1c). Results: LNM was observed in 87 cases (40.8%). Overall, periA/V demonstrated high sensitivity (97.7%) and negative predictive value (NPV; 93.5%). In pT1 tumors (n = 130), periA/V achieved 100% sensitivity and 100% NPV (27/27), and was consistently present in all node-positive pT1b–c tumors. In multivariate analyses, periA/V remained independently associated with LNM in the pT1 group (odds ratio [OR]: 16.08, p = 0.003) and pT1c subgroup (OR: 14.7, p = 0.010). In pT2–4 tumors, periA/V became frequent regardless of nodal status, indicating reduced discriminatory value. Conclusions: In this exploratory single-center cohort, EVG-based periA/V demonstrated high sensitivity for LNM in pT1 IBC-NSTs, with periA/V negativity consistently observed among node-negative cases. These preliminary findings suggest that periA/V may potentially contribute to LNM risk assessment in early-stage breast cancer.

6 March 2026 in Cancers
Verified
Journal Article
Open access
PDF file
Masakuni NoguchiMasakuni Noguchi
Masakuni Noguchi
YHYusuke Haba
Yusuke Haba
EMEmi Morioka
Emi Morioka
MIMasafumi Inokuchi
Masafumi Inokuchi
Background: Tailored axillary surgery (TAS) and axillary reverse mapping (ARM)-guided axillary lymph node dissection (ALND) have been developed to avoid arm lymphedema without increasing a risk of axillary recurrence. However, the oncological feasibility of TAS and ARM-guided ALND remains a crucial consideration. Methods: This article reviewed the oncological feasibility of TAS and ARM-guided ALND based on the current literature. Results: For ALND performed after TAS, additional involved nodes were found in 70% of upfront surgery patients and 60% of neoadjuvant chemotherapy (NAC) patients. ARM nodes were also involved in up to 64.7% of patients after ALND. However, it is not necessary to preserve all ARM nodes and lymphatics because multiple ARM lymphatic pathways exist. Selective preservation of ARM nodes closest to the axillary vein significantly reduced the incidence of involved ARM nodes (from 64.7% to 15.7%). Conclusions: TAS and ARM-guided ALND remain much less radical than ALND. However, residual nodal disease after TAS or ARM-guided ALND does not always develop axillary recurrence. Postoperative irradiation is effective in achieving local control in patients with low-volume (microscopic) residual nodal disease after TAS or ARM-guided ALND. We await the long-term results of prospective randomized clinical trials comparing TAS and ARM-guided ALND with conventional ALND.